

IN THE CLAIMS

Please amend the claims to read as follows:

1. (currently amended) An isolated ~~or substantially pure~~ OMP106 polypeptide, between 70% and 99% pure by weight, which is an outer membrane polypeptide of *Moraxella catarrhalis*, and which is extractable from intact cells at room temperature in 1.25% w/v n-octyl glucoside and which has a molecular weight of about 180 kD to about 230 kD as determined in SDS polyacrylamide gel electrophoresis using rabbit skeletal muscle myosin and *E. coli* β -galactosidase as the 200 kD and 116.25 kD molecular weight standards, respectively.
2. (original) The OMP106 polypeptide of claim 1, which has a molecular weight of about 190 kD.
3. (original) the OMP106 polypeptide of claim 1, which is an outer membrane polypeptide of *Moraxella catarrhalis* strain selected from the group consisting of ATCC 25238, ATCC 25240, ATCC 43617, ATCC 43618, ATCC 43627, ATCC 43628 and ATCC 49143.
4. (currently amended) The OMP106 polypeptide of claim 3, in which said *Moraxella catarrhalis* strain is ATCC 49143.
5. (currently amended) The OMP106 polypeptide of claim 3, wherein the *Moraxella catarrhalis* strain is a hemagglutinating cultivar.
6. (original) The OMP106 polypeptide of claim 1, which reacts with silver stain.
7. (previously presented) The OMP106 polypeptide of claim 1, which specifically binds an antibody that specifically binds the sequence of SEQ ID NO: 1.

8. (previously presented) The OMP106 polypeptide of claim 1, which specifically binds an antibody that specifically binds the sequence of SEQ ID NO: 11.
- 9-12. (cancelled)
13. (withdrawn) An isolated antibody that specifically binds the OMP106 polypeptide of claim 1 or a fragment thereof.
14. (withdrawn) An isolated antibody that specifically binds the OMP106 polypeptide of claim 9 or a fragment thereof.
15. (withdrawn) An isolated antibody that specifically binds the OMP106 polypeptide of claim 11 or a fragment thereof.
16. (withdrawn) The isolated antibody of claim 13 or 14, which is a cytotoxic antibody that mediates complement killing of *Moraxella catarrhalis*.
- 17-26. (cancelled)
27. (withdrawn) A method of producing an immune response in an animal comprising immunizing the animal with an effective amount of the OMP106 polypeptide of any of claims 1, 2, or 5.
28. (Cancelled)
29. (withdrawn) A method of producing a non-hemagglutinating cultivar of *M. catarrhalis* from a HA . *M. catarrhalis* strain or cultivar, which comprises serially passaging a HA *M. catarrhalis* strain or cultivar in static liquid cultures.
- 30-34. (cancelled)
35. (withdrawn) An isolated antibody that specifically binds the OMP 106 polypeptide of claim 33 or a fragment thereof.
- 36-39. (cancelled)

40. (withdrawn) A method of producing an immune response in an animal comprising immunizing an animal with an effective amount of the OMP106 polypeptide of claim 34.
- 41-51. (cancelled)
52. (currently amended) The OMP106 polypeptide of claim 1, which specifically binds an antibody that specifically binds the sequence of SEQ ID NO: 9.~~SEQ ID NO: 10.~~
53. (previously presented) An antigenic composition comprising the OMP106 polypeptide of claim 52.
54. (previously presented) An antigenic composition comprising the OMP106 polypeptide of claim 52 and a pharmaceutically acceptable carrier.
- 55-56. (cancelled)
57. (new) An isolated OMP106 polypeptide, between 70% and 99% pure by weight, which is an outer membrane polypeptide of *Moraxella catarrhalis* and which is extractable from intact cells at room temperature in 1.25% w/v n-octyl glucoside and which comprises an amino acid sequence selected from the group consisting of:
- A. SEQ ID NO: 1;
 - B. A sequence which is at least 80% but less than 100% identical to SEQ ID NO: 1;
 - C. SEQ ID NO: 9;
 - D. A sequence which is at least 80% but less than 100% identical to SEQ ID NO: 9;
 - E. SEQ ID NO: 11; and
 - F. A sequence which is at least 80% but less than 100% identical to SEQ ID NO: 11.

58. (new) An isolated OMP-106 polypeptide fragment consisting of 6 or more continuous amino acid residues of the sequence shown in SEQ ID NO: 1 wherein said fragment is recognized by an antibody that specifically binds a polypeptide comprising SEQ ID NO: 1.
59. (new) A recombinant OMP-106 polypeptide producible by a transformed host containing an expression vector comprising a nucleic acid sequence which encodes an amino acid sequence selected from the group consisting of:
- A. SEQ ID NO: 1;
 - B. A sequence which is at least 80% but less than 100% identical to SEQ ID NO: 1;
 - C. SEQ ID NO: 9;
 - D. A sequence which is at least 80% but less than 100% identical to SEQ ID NO: 9;
 - E. SEQ ID NO: 11; and
 - F. A sequence which is at least 80% but less than 100% identical to SEQ ID NO: 11.
60. (new) An antigenic composition comprising the OMP106 polypeptide of any one of claims 1, 2, 3, 4, 5, 6, 7, 8, 52, 53, 54, 57, 58 or 59.
61. (new) The antigenic composition of claim 61 further comprising a pharmaceutically acceptable carrier.
62. (new) An immunogenic composition comprising the OMP106 polypeptide of any one of claims 1, 2, 3, 4, 5, 6, 7, 8, 52, 53, 54, 57, 58 or 59.

63. (new) The immunogenic composition of claim 63 further comprising a pharmaceutically acceptable carrier.